You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
The deal includes key testing services like Transplant's TruGraf blood test and Viracor's TRAC test, along with Viracor Eurofins' new SARS-CoV-2 test.
The San Francisco-based startup believes that its QiSant assay could help guide the use of immunosuppressive drugs and other therapies to prevent kidney transplant rejection.
The RT-qPCR test was made available last week after validation in accordance with the US Food and Drug Administration's Emergency Use Authorization guidance.
The company's original lawsuit, filed last March, accused Natera of infringing on two patents it holds in conjunction with Stanford University.
The company said testing revenues rose 54 percent during the quarter, and that it provided 63 percent more patient results year over year.
The increase in total revenues was driven primarily by sales of Natera's Panorama and Horizon reproductive health tests.
CareDx first sued Natera in April 2019, accusing the company of trying to mislead patients and clinicians about the superiority of its Prospera transplant test.
The Milwaukee, Wisconsin-based firm is part of a growing biotech ecosystem in the region, which has particular expertise in transplant medicine.
The test adds to a menu of transplant monitoring assays that includes cytomegalovirus, Epstein-Barr virus, and BK virus.
The patent, which was awarded Jan. 7, covers cell-free DNA-based diagnostic methods, including those used in transplant medicine.